RxSight, Inc. achieved a 41% increase in Q4 2024 revenue to $40.2 million, primarily due to a 61% rise in LAL procedure volume and a 46% expansion in LDD installed base. The company also reported a significant improvement in net loss and gross profit margin compared to the previous year.
Fourth quarter 2024 revenue increased by 41% to $40.2 million, compared to $28.6 million in Q4 2023.
Gross profit for Q4 2024 was $28.8 million, or 71.6% of revenue, up from $17.7 million or 61.8% in Q4 2023.
Net loss for Q4 2024 improved to $(5.9) million, or $(0.15) per share, from $(9.2) million, or $(0.26) per share, in Q4 2023.
Adjusted net earnings for Q4 2024 were $1.3 million, or $0.03 per share, compared to an adjusted net loss of $(4.8) million, or $(0.13) per share, in Q4 2023.
RxSight, Inc. reiterated its full-year 2025 guidance, projecting continued growth in revenue and gross profit margin, while managing operating expenses.
Analyze how earnings announcements historically affect stock price performance